» Articles » PMID: 29880241

Vaccine-preventable Diseases, Vaccines and Guillain-Barre' Syndrome

Overview
Journal Vaccine
Date 2018 Jun 9
PMID 29880241
Citations 31
Authors
Affiliations
Soon will be listed here.
Abstract

Guillain-Barré syndrome (GBS) is an acute, immune-mediated polyradiculoneuropathy. Infections and vaccines have been hypothesized to play a role in triggering GBS development. These beliefs can play a role in reducing vaccination coverage. In this report, data concerning this hypothesis are discussed. It is shown that an association between vaccine administration and GBS has never been proven for most of debated vaccines, although it cannot be definitively excluded. The only exception is the influenza vaccine, at least for the preparation used in 1976. For some vaccines, such as measles/mumps/rubella, human papillomavirus, tetravalent conjugated meningococcal vaccine, and influenza, the debate between supporters and opponents of vaccination remains robust and perception of vaccines' low safety remains a barrier to achieving adequate vaccination coverage. Less than 1 case of GBS per million immunized persons might occur for these vaccines. However, in some casesimmunization actually reduces the risk of GBS development. In addition, the benefits of vaccination are clearly demonstrated by the eradication or enormous decline in the incidence of many vaccine-preventable diseases. These data highlight that the hypothesized risks of adverse events, such as GBS, cannot be considered a valid reason to avoid the administration of currently recommended vaccines.

Citing Articles

Post-Shingrix Vaccination Guillain-Barré Syndrome Presentation in the Emergency Department: A Case Report and Literature Review.

Drmota J, Quader K, Naeem S Cureus. 2025; 17(1):e77777.

PMID: 39981465 PMC: 11841657. DOI: 10.7759/cureus.77777.


Guillain-Barré syndrome.

Leonhard S, Papri N, Querol L, Rinaldi S, Shahrizaila N, Jacobs B Nat Rev Dis Primers. 2024; 10(1):97.

PMID: 39702645 DOI: 10.1038/s41572-024-00580-4.


[COVID-19 vaccine safety: results of active surveillance at a sentinel site in ArgentinaSegurança das vacinas contra COVID-19: resultados da vigilância ativa em uma unidade sentinela da Argentina].

Lescura N, Selent C, Guerci M, Bertachini O, Lopez M, de Prada A Rev Panam Salud Publica. 2024; 48:e94.

PMID: 39687241 PMC: 11648208. DOI: 10.26633/RPSP.2024.94.


Global burden of vaccine-associated Guillain-Barré syndrome over 170 countries from 1967 to 2023.

Jeong Y, Park S, Lee S, Jang W, Park J, Lee K Sci Rep. 2024; 14(1):24561.

PMID: 39427003 PMC: 11490553. DOI: 10.1038/s41598-024-74729-2.


Toxicologic Pathology Forum: mRNA Vaccine Safety-Separating Fact From Fiction.

Sellers R, Dormitzer P Toxicol Pathol. 2024; 52(6):333-342.

PMID: 39254115 PMC: 11528946. DOI: 10.1177/01926233241278298.